Diabetes Care (2010) 33(4):e588
In other words, your medication may not provide the same benefits or continue helping you manage your diabetes
Yago K, Tanaka Y, Asanami S
It was designed to have potent activity on both the GLP-1 and GIP receptors but with minimal to no -arrestin recruitment on either receptor
In this context, GLP-1based pharmacotherapies have emerged as a valuable adjunct to lifestyle modification, with growing evidence supporting their role in improving weight-related and cardiometabolic outcomesThis review has examined the mechanisms of action, clinical efficacy, safety considerations, and future directions of GLP-1 single, dual, and triple agonists, with a focus on their potential relevance to adolescent obesity management